Cargando…
Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers
Room for improvement exists regarding recommendations for screening, staging, therapy selection, and frequency of surveillance of gastrointestinal cancers. Screening is costly and invasive, improved staging demands increased sensitivity and specificity to better guide therapy selection. Surveillance...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721625/ https://www.ncbi.nlm.nih.gov/pubmed/31412682 http://dx.doi.org/10.3390/cancers11081164 |
_version_ | 1783448384622821376 |
---|---|
author | Jacobson, Richard A. Munding, Emily Hayden, Dana M. Levy, Mia Kuzel, Timothy M. Pappas, Sam G. Masood, Ashiq |
author_facet | Jacobson, Richard A. Munding, Emily Hayden, Dana M. Levy, Mia Kuzel, Timothy M. Pappas, Sam G. Masood, Ashiq |
author_sort | Jacobson, Richard A. |
collection | PubMed |
description | Room for improvement exists regarding recommendations for screening, staging, therapy selection, and frequency of surveillance of gastrointestinal cancers. Screening is costly and invasive, improved staging demands increased sensitivity and specificity to better guide therapy selection. Surveillance requires increased sensitivity for earlier detection and precise management of recurrences. Peripherally collected blood-based liquid biopsies enrich and analyze circulating tumor cells and/or somatic genomic material, including circulating tumor DNA along with various subclasses of RNA. Such assays have the potential to impact clinical practice at multiple stages of management in gastrointestinal cancers. This review summarizes current basic and clinical evidence for the utilization of liquid biopsy in cancers of the esophagus, pancreas, stomach, colon, and rectum. Technical aspects of various liquid biopsy methodologies and targets are reviewed and evidence supporting current commercially available assays is examined. Finally, current clinical applicability, potential future uses, and pitfalls of applying liquid biopsy to the screening, staging and therapeutic management of these diseases are discussed. |
format | Online Article Text |
id | pubmed-6721625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67216252019-09-10 Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers Jacobson, Richard A. Munding, Emily Hayden, Dana M. Levy, Mia Kuzel, Timothy M. Pappas, Sam G. Masood, Ashiq Cancers (Basel) Review Room for improvement exists regarding recommendations for screening, staging, therapy selection, and frequency of surveillance of gastrointestinal cancers. Screening is costly and invasive, improved staging demands increased sensitivity and specificity to better guide therapy selection. Surveillance requires increased sensitivity for earlier detection and precise management of recurrences. Peripherally collected blood-based liquid biopsies enrich and analyze circulating tumor cells and/or somatic genomic material, including circulating tumor DNA along with various subclasses of RNA. Such assays have the potential to impact clinical practice at multiple stages of management in gastrointestinal cancers. This review summarizes current basic and clinical evidence for the utilization of liquid biopsy in cancers of the esophagus, pancreas, stomach, colon, and rectum. Technical aspects of various liquid biopsy methodologies and targets are reviewed and evidence supporting current commercially available assays is examined. Finally, current clinical applicability, potential future uses, and pitfalls of applying liquid biopsy to the screening, staging and therapeutic management of these diseases are discussed. MDPI 2019-08-13 /pmc/articles/PMC6721625/ /pubmed/31412682 http://dx.doi.org/10.3390/cancers11081164 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jacobson, Richard A. Munding, Emily Hayden, Dana M. Levy, Mia Kuzel, Timothy M. Pappas, Sam G. Masood, Ashiq Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers |
title | Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers |
title_full | Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers |
title_fullStr | Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers |
title_full_unstemmed | Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers |
title_short | Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers |
title_sort | evolving clinical utility of liquid biopsy in gastrointestinal cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721625/ https://www.ncbi.nlm.nih.gov/pubmed/31412682 http://dx.doi.org/10.3390/cancers11081164 |
work_keys_str_mv | AT jacobsonricharda evolvingclinicalutilityofliquidbiopsyingastrointestinalcancers AT mundingemily evolvingclinicalutilityofliquidbiopsyingastrointestinalcancers AT haydendanam evolvingclinicalutilityofliquidbiopsyingastrointestinalcancers AT levymia evolvingclinicalutilityofliquidbiopsyingastrointestinalcancers AT kuzeltimothym evolvingclinicalutilityofliquidbiopsyingastrointestinalcancers AT pappassamg evolvingclinicalutilityofliquidbiopsyingastrointestinalcancers AT masoodashiq evolvingclinicalutilityofliquidbiopsyingastrointestinalcancers |